Christine Schmid-Tannwald
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 11 | 2024 | 736 | 3.960 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 18 | 2024 | 294 | 3.880 |
Why?
|
| Neuroendocrine Tumors | 7 | 2023 | 105 | 3.590 |
Why?
|
| Contrast Media | 12 | 2023 | 1078 | 1.490 |
Why?
|
| Organometallic Compounds | 3 | 2023 | 132 | 1.390 |
Why?
|
| Pancreatic Neoplasms | 3 | 2023 | 645 | 1.270 |
Why?
|
| Brachytherapy | 3 | 2024 | 119 | 1.130 |
Why?
|
| Positron-Emission Tomography | 9 | 2023 | 329 | 0.990 |
Why?
|
| Positron Emission Tomography Computed Tomography | 6 | 2023 | 86 | 0.980 |
Why?
|
| Colorectal Neoplasms | 3 | 2024 | 938 | 0.980 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2023 | 9 | 0.960 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2023 | 549 | 0.940 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2023 | 3362 | 0.910 |
Why?
|
| Gadolinium DTPA | 8 | 2015 | 261 | 0.830 |
Why?
|
| Liver Diseases | 2 | 2013 | 238 | 0.780 |
Why?
|
| Diagnostic Imaging | 3 | 2023 | 469 | 0.750 |
Why?
|
| Retrospective Studies | 21 | 2024 | 8489 | 0.730 |
Why?
|
| Liver | 3 | 2014 | 1230 | 0.720 |
Why?
|
| Tyrosine | 6 | 2016 | 133 | 0.690 |
Why?
|
| Image Enhancement | 5 | 2015 | 563 | 0.670 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 238 | 0.660 |
Why?
|
| Crohn Disease | 1 | 2023 | 730 | 0.590 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2023 | 384 | 0.540 |
Why?
|
| Liver Abscess | 1 | 2014 | 12 | 0.490 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 353 | 0.480 |
Why?
|
| Humans | 40 | 2024 | 86643 | 0.470 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 106 | 0.470 |
Why?
|
| Middle Aged | 25 | 2023 | 25028 | 0.460 |
Why?
|
| Diagnosis, Differential | 7 | 2016 | 1565 | 0.440 |
Why?
|
| Radiosurgery | 2 | 2016 | 272 | 0.430 |
Why?
|
| Male | 27 | 2023 | 40965 | 0.400 |
Why?
|
| Fistula | 1 | 2011 | 42 | 0.400 |
Why?
|
| Reproducibility of Results | 9 | 2023 | 2705 | 0.380 |
Why?
|
| Brain Neoplasms | 4 | 2016 | 763 | 0.360 |
Why?
|
| Sensitivity and Specificity | 9 | 2023 | 1991 | 0.360 |
Why?
|
| Observer Variation | 5 | 2015 | 602 | 0.350 |
Why?
|
| Glioma | 3 | 2016 | 285 | 0.330 |
Why?
|
| Aged | 15 | 2020 | 18415 | 0.320 |
Why?
|
| Female | 23 | 2020 | 44532 | 0.320 |
Why?
|
| Intestine, Small | 2 | 2023 | 303 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 1313 | 0.310 |
Why?
|
| Adult | 18 | 2020 | 25648 | 0.310 |
Why?
|
| Prostatic Neoplasms | 5 | 2023 | 1721 | 0.310 |
Why?
|
| Receptors, Somatostatin | 2 | 2023 | 33 | 0.300 |
Why?
|
| Gallium Radioisotopes | 2 | 2023 | 32 | 0.290 |
Why?
|
| Intestines | 2 | 2023 | 411 | 0.270 |
Why?
|
| Prognosis | 4 | 2023 | 3679 | 0.240 |
Why?
|
| Intestine, Large | 1 | 2023 | 16 | 0.240 |
Why?
|
| Abdomen | 3 | 2013 | 122 | 0.230 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 64 | 0.230 |
Why?
|
| AIDS Dementia Complex | 1 | 2022 | 8 | 0.220 |
Why?
|
| Gadolinium | 2 | 2013 | 103 | 0.220 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 318 | 0.210 |
Why?
|
| ROC Curve | 5 | 2016 | 752 | 0.210 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 6509 | 0.200 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 1 | 2020 | 2 | 0.190 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2020 | 11 | 0.190 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2015 | 663 | 0.190 |
Why?
|
| Forensic Medicine | 1 | 2020 | 6 | 0.190 |
Why?
|
| Hyoid Bone | 1 | 2020 | 12 | 0.190 |
Why?
|
| Dementia | 1 | 2022 | 187 | 0.190 |
Why?
|
| Larynx | 1 | 2020 | 38 | 0.180 |
Why?
|
| Multidetector Computed Tomography | 1 | 2020 | 54 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2021 | 751 | 0.170 |
Why?
|
| Treatment Outcome | 4 | 2021 | 7993 | 0.170 |
Why?
|
| Fractures, Bone | 1 | 2020 | 131 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 1204 | 0.150 |
Why?
|
| Reference Standards | 2 | 2015 | 159 | 0.150 |
Why?
|
| Radiopharmaceuticals | 2 | 2016 | 180 | 0.140 |
Why?
|
| Diverticulitis | 1 | 2015 | 9 | 0.140 |
Why?
|
| Watchful Waiting | 1 | 2016 | 60 | 0.130 |
Why?
|
| Subtraction Technique | 1 | 2016 | 133 | 0.130 |
Why?
|
| Diverticulum | 1 | 2015 | 44 | 0.130 |
Why?
|
| Astrocytoma | 1 | 2015 | 82 | 0.120 |
Why?
|
| Acute Disease | 1 | 2016 | 826 | 0.120 |
Why?
|
| Exudates and Transudates | 1 | 2014 | 14 | 0.120 |
Why?
|
| Patient Positioning | 1 | 2015 | 63 | 0.120 |
Why?
|
| HIV Infections | 1 | 2022 | 772 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2014 | 289 | 0.120 |
Why?
|
| Astrocytes | 1 | 2013 | 139 | 0.110 |
Why?
|
| Meglumine | 1 | 2013 | 39 | 0.110 |
Why?
|
| Seminal Vesicles | 1 | 2013 | 39 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2016 | 971 | 0.110 |
Why?
|
| Biopsy | 2 | 2013 | 1163 | 0.110 |
Why?
|
| Pregnancy, Ectopic | 1 | 2012 | 36 | 0.110 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 244 | 0.110 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2012 | 96 | 0.110 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 307 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2014 | 839 | 0.100 |
Why?
|
| Fibrosis | 1 | 2013 | 203 | 0.100 |
Why?
|
| Intestinal Fistula | 1 | 2011 | 30 | 0.100 |
Why?
|
| Abdominal Abscess | 1 | 2011 | 22 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 146 | 0.100 |
Why?
|
| Pancreas | 1 | 2013 | 239 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 426 | 0.090 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 297 | 0.090 |
Why?
|
| Kidney | 2 | 2015 | 1241 | 0.090 |
Why?
|
| Patient Safety | 1 | 2013 | 212 | 0.090 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 332 | 0.090 |
Why?
|
| Sickness Impact Profile | 1 | 2009 | 27 | 0.090 |
Why?
|
| Cell Membrane | 1 | 2013 | 666 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2014 | 267 | 0.090 |
Why?
|
| Vision, Ocular | 1 | 2009 | 71 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 1939 | 0.090 |
Why?
|
| Eye Diseases | 1 | 2009 | 53 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 574 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 621 | 0.090 |
Why?
|
| Adolescent | 4 | 2020 | 8981 | 0.080 |
Why?
|
| Time Factors | 2 | 2014 | 5210 | 0.080 |
Why?
|
| Algorithms | 1 | 2014 | 1830 | 0.070 |
Why?
|
| Biological Transport | 2 | 2016 | 396 | 0.060 |
Why?
|
| Prostatectomy | 3 | 2013 | 471 | 0.060 |
Why?
|
| Young Adult | 4 | 2020 | 5976 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 357 | 0.060 |
Why?
|
| Radiologists | 1 | 2023 | 46 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2023 | 2601 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2023 | 220 | 0.050 |
Why?
|
| Kinetics | 2 | 2015 | 1513 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2022 | 29 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 138 | 0.050 |
Why?
|
| Quality of Life | 1 | 2009 | 1585 | 0.050 |
Why?
|
| Adrenalectomy | 1 | 2020 | 43 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 454 | 0.050 |
Why?
|
| Pituitary Gland | 1 | 2020 | 117 | 0.050 |
Why?
|
| Autopsy | 1 | 2020 | 116 | 0.050 |
Why?
|
| Pregnancy | 2 | 2020 | 2894 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 277 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 989 | 0.040 |
Why?
|
| Neoplasms | 1 | 2013 | 2898 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 1139 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2016 | 70 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2016 | 63 | 0.040 |
Why?
|
| Whole Body Imaging | 1 | 2015 | 41 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 364 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 2767 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 66 | 0.030 |
Why?
|
| Pregnancy, Heterotopic | 1 | 2012 | 3 | 0.030 |
Why?
|
| Pregnancy, Abdominal | 1 | 2012 | 5 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 2012 | 41 | 0.030 |
Why?
|
| Cicatrix | 1 | 2012 | 63 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 334 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 674 | 0.030 |
Why?
|
| Rectum | 1 | 2013 | 146 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2012 | 137 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 303 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 4213 | 0.030 |
Why?
|
| Ascites | 1 | 2011 | 55 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 552 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 1204 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 695 | 0.020 |
Why?
|
| National Eye Institute (U.S.) | 1 | 2009 | 1 | 0.020 |
Why?
|
| Germany | 1 | 2009 | 72 | 0.020 |
Why?
|
| Population Groups | 1 | 2009 | 41 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1531 | 0.020 |
Why?
|
| Child | 1 | 2020 | 6927 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1673 | 0.020 |
Why?
|
| Prevalence | 1 | 2009 | 1239 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2360 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 1621 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 2501 | 0.010 |
Why?
|
| United States | 1 | 2009 | 6672 | 0.010 |
Why?
|